BusinessGlobal Diabetes and Obesity Drugs Market to reach $163.2 Billion by 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment: ResearchMozBy Nasdaq OMXSep 7, 2016, 12:01 PM UTC